- Home
- RNA vs SPR Comparison
RNA vs SPR Comparison
Compare RNA & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- SPR
- Stock Information
- Founded
- RNA 2012
- SPR 1927
- Country
- RNA United States
- SPR United States
- Employees
- RNA N/A
- SPR N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- SPR Military/Government/Technical
- Sector
- RNA Health Care
- SPR Industrials
- Exchange
- RNA Nasdaq
- SPR Nasdaq
- Market Cap
- RNA 4.0B
- SPR 4.7B
- IPO Year
- RNA 2020
- SPR 2006
- Fundamental
- Price
- RNA $46.92
- SPR $41.17
- Analyst Decision
- RNA Strong Buy
- SPR Hold
- Analyst Count
- RNA 15
- SPR 2
- Target Price
- RNA $68.40
- SPR $38.63
- AVG Volume (30 Days)
- RNA 3.7M
- SPR 693.8K
- Earning Date
- RNA 08-07-2025
- SPR 08-05-2025
- Dividend Yield
- RNA N/A
- SPR N/A
- EPS Growth
- RNA N/A
- SPR N/A
- EPS
- RNA N/A
- SPR N/A
- Revenue
- RNA $10,729,000.00
- SPR $6,278,800,000.00
- Revenue This Year
- RNA N/A
- SPR $24.21
- Revenue Next Year
- RNA $196.18
- SPR $14.89
- P/E Ratio
- RNA N/A
- SPR N/A
- Revenue Growth
- RNA 1.23
- SPR N/A
- 52 Week Low
- RNA $21.51
- SPR $27.00
- 52 Week High
- RNA $56.00
- SPR $42.33
- Technical
- Relative Strength Index (RSI)
- RNA 71.22
- SPR 59.00
- Support Level
- RNA $45.06
- SPR $39.50
- Resistance Level
- RNA $47.24
- SPR $41.19
- Average True Range (ATR)
- RNA 2.58
- SPR 0.83
- MACD
- RNA 0.50
- SPR 0.03
- Stochastic Oscillator
- RNA 81.95
- SPR 59.01
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.